US5204108A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Transmucosal formulations of low molecular weight peptide drugs
Assignee: Kyowa Kirin Services Ltd
•
Filing: 1988-10-10
•
Granted: 1993-04-20
•
Expires: 2008-10-10
Abstract
Abstract A drug delivery composition comprising a plurality of microspheres and active drug associated with each microsphere, the drug being for systemic delivery and having a maximum molecular weight of 6000, and the composition being substantially free of an enhancer. The microspheres may be of starch, gelatin or albumin. Suitable drugs include peptides, such as insulin, and antigenic vaccine ingredients. The compositions are suitable for delivery across a mucosal surface such as the vagina, eye or nose.
Inventors
- 👤 Lisbeth Illum
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 04:57
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1658; A61K9/1652
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
70 words
A drug delivery composition which is suitable for transmucosal delivery and which comprises a plurality of microspheres adapted to gel in contact with the mucosal surface and active drug associated with each microsphere, the composition being substantially free of an enhancer, characterised in that the drug is for systemic delivery and is a peptide having a maximum molecular weight of 6000, and the microspheres comprise starch, gelatin, collagen or dextran.
Claim 2
Dependent Claim
70 words
A drug delivery composition which is suitable for transmucosal delivery and which comprises a plurality of microspheres adapted to gel in contact with the mucosal surface and active drug associated with each microsphere, the composition being substantially free of an enhancer, characterised in that the drug is for systemic delivery and is a peptide having a maximum molecular weight of 6000, and the microspheres comprise starch, gelatin, collagen or dextran.
Claim 3
Dependent Claim
26 words
A drug delivery composition as claimed in claim 1 in which the microspheres are starch microspheres of an average diameter of between 10 and 100 μm.
Claim 4
Dependent Claim
18 words
A drug delivery composition as claimed in claim 1 wherein the microsphere material is at least partially cross-linked.
Claim 5
Dependent Claim
19 words
A drug delivery composition as claimed in claim 1 wherein the microspheres are formed from the active drug itself.
Claim 6
Dependent Claim
19 words
A drug delivery composition as claimed in claim 1 wherein the microspheres are suitable for administration to the vagina.
Claim 7
Dependent Claim
19 words
A drug delivery composition as claimed in claim 1 wherein the microspheres are suitable for administration to the eye.
Claim 8
Dependent Claim
20 words
A drug delivery composition as claimed in claim 1 wherein the microspheres are suitable for delivery to the nasal mucosa.
Claim 9
Dependent Claim
14 words
A drug delivery composition as claimed in claim 1 and which is a vaccine.
Claim 10
Dependent Claim
19 words
A drug delivery composition according to claim 1 wherein the peptide has a molecular weight of at least 1000.
Claim 11
Dependent Claim
17 words
A drug delivery composition as claimed in claim 1 wherein the peptide is insulin or a calcitonin.
Claim 12
Dependent Claim
21 words
A drug delivery composition as claimed in claim 1 wherein the drug is associated with the microspheres by being incorporated therein.
Claim 13
Dependent Claim
22 words
A drug delivery composition as claimed in claim 11 wherein the drug is incorporated into the microspheres during preparation of the microspheres.
Claim 14
Dependent Claim
22 words
A drug delivery composition as claimed in claim 11 wherein the drug is incorporated into the microspheres after preparation of the microspheres.
References Cited (Backward Citations)
FR2081353A1
Cited
GB1516348A
Cited
US4250163A
Cited
EP0023359A2
Cited
GB2055578A
Cited
EP0038979A1
Cited
EP0069399A2
Cited
EP0084898B1
Cited
EP0114577A1
Cited
US4613500A
Cited
EP0122036A1
Cited
EP0130577A2
Cited
EP0170642A2
Cited
GB2176105A
Cited
WO1987003197A1
Cited
EP0230264A2
Cited
EP0257915A1
Cited
WO1988004556A1
Cited
GB2200368A
Cited
US4816443A
Cited
EP0312052A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-19 | 1996-10-19 | 1997-04-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-19 | 2000-10-19 | 2001-04-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-19 | 2004-10-19 | 2005-04-20 | $7700.00 | Window Closed / Lapsed |